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Background: Adverse reactions, particularly injec-
tion site reactions (ISRs), are common reasons for
nonadherence to injectable multiple sclerosis (MS)
treatments. Adherence to MS treatment is important
to ensure good treatment outcomes.
Objective: The aim of this study was to assess the
local tolerability of subcutaneous (SC) serum-free inter-
feron (IFN) β-1a in patients with relapsing MS over
1 year in a real-life, international setting. The study also
assessed safety, disease activity, and adherence.
Methods: This was a prospective, international,
multicenter, observational study of 251 patients with
relapsing-remitting MS treated with SC serum-free
IFN β-1a 44 μg or 22 μg 3 times weekly for 12
months or until early discontinuation. The primary
end point was the proportion of patients with ISRs.
Secondary end points included proportion of patients
with adverse events (AEs); annualized relapse rateAccepted for publication April 4, 2014.
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1946(ARR); proportion of patients remaining relapse-free;
and adherence to treatment.
Results: During the observation period, 27.5% (69
of 251) of patients experienced nonserious ISRs,
which was consistent with the incidence reported in
clinical studies. Five patients discontinued treatment
and 2 patients suspended treatment because of ISRs.
Mean age was 35.8 years; patients were predomi-
nantly white (94.8%), and two thirds (66.1%) were
female. The overall incidence of AEs was 63.7% (160
of 251), and overall safety and tolerability were
assessed as excellent, very good, or good in 485%
of patients. More than 70% of patients remained
relapse-free, and the mean ARR was 0.4. More than
90% of patients had very good or good adherence to
treatment; a signiﬁcantly greater proportion of these
were relapse-free at 12 months compared with those
with fair or poor adherence (77.6% vs 50.0%; P ¼
0.0107), and their ARR was signiﬁcantly lower (0.3 vs
0.9; P ¼ 0.0055). Patients with fair or poor adherence
had 4.6 times higher odds of experiencing a relapse
than those with very good or good adherence.Scan the QR Code with your phone to obtain
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R. Hupperts et al.Conclusions: The incidence of ISRs and the overall
safety proﬁle in this observational study, in an interna-
tional population in a real-life setting, conﬁrm the good
local tolerability of SC serum-free IFN β-1a reported in
clinical studies. The association between good adher-
ence and a lower ARR underlines the importance of
good adherence. The good local and general tolerabil-
ity of SC IFN β-1a may help ensure a high level
of adherence, which is associated with better clinical
outcomes. ClinicalTrials.gov identiﬁer: NCT01080027.
(Clin Ther. 2014;36:1946–1957) & 2014 The Authors.
Published by Elsevier HS Journals, Inc.
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INTRODUCTION
Multiple sclerosis (MS) is a heterogeneous, immune-
mediated, demyelinating, neurodegenerative disease
and is the most common cause of neurologic disability
in young adults. It is a chronic and, as yet, incurable
disease that in its most common clinical form has a
relapsing-remitting course that necessitates lifelong
treatment. The chronic nature of MS makes treatment
adherence challenging, particularly in patients with
long-lasting disease.1 Nonadherence to MS treatments
has been well documented,2–4 with studies reporting
adherence rates between 28% and 87% among pa-
tients taking disease-modifying drugs.5 Several studies
have demonstrated that patients with MS who have
gaps in their treatment have a higher risk of relapse
than those with better adherence,6–9 indicating that
adherence to prescribed therapy is important to ensure
clinical efﬁcacy.
The established ﬁrst-line immunomodulatory
disease-modifying drugs, namely interferon (IFN) β
and glatiramer acetate, have been shown to modify
the course of MS and have established beneﬁt-to-risk
proﬁles that make them suitable for long-term use from
the initial diagnosis of the disease.10–16 IFN β prepara-
tions and glatiramer acetate are administered by sub-
cutaneous (SC) or intramuscular injection, and some
studies have reported that factors related to self-
injection can have a negative effect on patients’ quality
of life and on their adherence to medication.17,18 Skin
reactions and pain at the injection site are commonly
cited reasons for nonadherence to injectable MS thera-
pies.1,3,19 In 1 study, 12% of patients who interrupted
IFN β treatment for 41 month cited injection-siteDecember 2014reactions (ISRs) as the reason.4 In a survey of 2648
patients treated with injectable MS therapies, injection-
related adverse effects (including pain at the injection
site, injection anxiety, and fatigue with the injection
process) were the second most common reasons for
nonadherence (32% of nonadherent patients) after
forgetting to administer the injection (50.2%).20
The efﬁcacy and safety of serum-free SC IFN β-1a
have been demonstrated in closely monitored patient
populations in clinical trials.21,22 However, in daily
clinical practice, the patient population is more heter-
ogeneous and patients have less intensive monitoring
by health care professionals. The objectives of the
present study were therefore to evaluate the local
tolerability, general safety, and efﬁcacy of serum-free
SC IFN β-1a in patients with relapsing-remitting MS
(RRMS) and to assess patients’ adherence to treatment
over a 12-month period in an international population
in a real-life setting.
PATIENTS AND METHODS
Study Design
The STAR (Safety, Tolerability and Adherence with
Rebifs New Formulation in Real Life Settings) study
was a prospective, international, multicenter, obser-
vational study conducted in 47 centers in Finland,
Greece, the Netherlands, Norway, Portugal, and
Sweden between October 2008 and September 2011.
The study was performed in accordance with the
Declaration of Helsinki (Edinburgh 2000 version,
with the clariﬁcations of Washington 2002 and Tokyo
2004) and applicable national regulatory require-
ments. It was approved by local ethics committees
for the participating centers.
Participants
Patients diagnosed with RRMS according to the
2005 McDonald criteria23 were eligible for enrollment
in the study if they were aged 18 to 60 years; had a
scoreo6 on the Expanded Disability Status Scale; and
were treatment naive for any disease-modifying MS
therapy or hadr6 weeks of treatment with SC serum-
free IFN β-1a before enrollment. Patients were re-
quired to provide written informed consent before
study initiation.
Patients were excluded from the study24 if they had
Z1 of the following criteria: primary progressive or
secondary progressive MS; previously administered
IFN β, glatiramer acetate, any other immunomo-1947
Clinical Therapeuticsdulatory or immunosuppressive agents, or any other MS
therapy in the past, with the exception of serum-free SC
IFN β-1a for no more than 6 weeks before enrollment;
received oral or systemic corticosteroids or adrenocorti-
cotropic hormone within the 30 days before enrollment;
history of any chronic pain syndrome; serious or acute
heart disease; inadequate liver function (deﬁned as an
alanine aminotransferase level 43  upper limit of
normal [ULN], alkaline phosphatase 42  ULN, or
total bilirubin 42  ULN if associated with any
elevation of alanine aminotransferase or alkaline phos-
phatase); white blood cell count o0.5  the lower limit
of normal; a history of alcohol or drug abuse in the last 2
years; or contraindications to IFN β-1a as deﬁned in the
product labeling information. Patients were recruited
over a 1-year period, and each patient was observed
for 12 months or until early termination.
Administration of the Study Drug
All patients received SC serum-free (without fetal
bovine or human serum albumin excipients) IFN β-1a†
44 μg or 22 μg 3 times weekly throughout the study
period. Serum-free SC IFN β-1a could be administered by
using an autoinjection device or by manual injection. The
decision on the prescribed dose of serum-free IFN β-1a
was at the discretion of the treating physician and
reﬂected the current standard of care in a real-life setting.
Patient Assessment
After a prestudy visit to assess eligibility, patients were
required to attend the clinic at study day 1 (baseline),
month 6, and month 12 or at any time in the case of
early discontinuation (ED). At study day 1, each patient
was provided with a diary for reporting experiences with
the medication and missed injections (including reasons
for missed injections). In addition, demographic data and
information on signiﬁcant medical history/concomitant
diseases, MS history, concomitant MS medication, vital
signs, details of current treatment with SC serum-free
IFN β-1a, and adverse events (AEs) were gathered. The
following data were recorded at the month 6 and month
12 visits: concomitant MS medication; vital signs; AEs;
adherence to therapy; and details of serum-free IFN β-1a
treatment. At the month 12 visit, the investigator
performed a global evaluation of safety and adherence
for each patient.†Trademark: Rebifs (Merck Serono SA, Geneva, Switzerland, a
subsidiary of Merck KGaA, Darmstadt, Germany).
1948Criteria for Evaluation
The primary study end point was the proportion of
patients with ISRs. Secondary end points included the
proportion of patients with AEs, including speciﬁc
categories of AEs; the proportion of missed injections;
reasons for missed injections; annualized relapse rate
(ARR); the proportion of patients remaining relapse-
free from baseline; and time to ﬁrst relapse.
AEs were deﬁned according to World Health
Organization Adverse Reaction Terminology and were
displayed by using Medical Dictionary for Regula-
tory Activities system organ class and preferred term.
Causality was assessed in accordance with the recom-
mendations of the World Health Organization AE
Monitoring Centre.
A relapse was deﬁned as the appearance of a new
symptom or worsening of an old symptom attribut-
able to MS, accompanied by an appropriate new
neurologic abnormality or focal neurologic dysfunc-
tion lasting at least 24 hours in the absence of fever
and preceded by stability or improvement for at least
30 days. Maximal severity of relapses was described
according to the activities of daily living criteria.25
For the assessment of treatment adherence, patients
were asked to record the date of each missed injection
and the reason for missing the injection, and were
instructed to bring the diary with them at every visit.
The investigators assessed patients’ adherence as: very
good (patient was always taking his or her medication
as instructed by the physician); good (patient was
taking his or her medication as instructed by the
physician but forgot it once or twice since the previous
visit); fair (sometimes patient did not take the study
medication properly or regularly); or poor (patient did
not take the study medication properly or regularly
most of the time).
Sample Size Determination
A sample size of 250 patients was required to
estimate the incidence of ISRs in the study population
with an accuracy of 6%, based on an expected
incidence of ISRs of 30% in 48- and 96-week data
from clinical studies of serum-free SC IFN β-1a.22,26
Statistical Analysis
All analyses were performed on the safety popula-
tion, which included all patients who received at least
1 injection of serum-free IFN β-1a after enrollment.
All data were evaluated descriptively by using mean,Volume 36 Number 12
R. Hupperts et al.median, SD, quartiles, and extreme values for contin-
uous variables, and counts and percentages for cate-
gorical variables.
For the primary end point, the proportion of
patients with ISRs and corresponding 95% CIs were
determined. For the secondary end points, the out-
comes “presence/absence of ISR” and “relapse/re-
lapse free at study end” were analyzed by using
logistic regression. Time to onset of ﬁrst relapse was
analyzed by using a Cox proportional hazards
regression model, with time (days) as the dependent
variable, and level of adherence as the independent
variable with no interaction terms. Differences be-
tween subpopulations with regard to relapse data
were analyzed nonparametrically by using the Wil-
coxon rank sum test. Imputation was performed for
partial dates only.
RESULTS
Patient Disposition and Demographic and
Baseline Characteristics
Patient disposition is shown in Figure 1. A total of
254 patients were recruited to the study. The safety
population, which included patients with documentedPatients without documented
administration of SC IFN β-1a
(n = 3)
Early discontinuation of treatment*
(n = 42)









Figure 1. Patient disposition. *Percentages are based on
December 2014administration of SC IFN β-1a, comprised 251 patients;
ED was documented for 42 patients (16.7%), and 196
(78.1%) completed the month 12 visit. Adverse drug
reactions were the most common reason for early study
discontinuation (7.2% [18 of 251]).
Demographic and baseline disease characteristics of
the safety population are summarized in Table I.
Mean (SD) age was 35.8 (10.3) years (n ¼ 251);
patients were predominantly white (94.8% [238 of
251]), and two thirds were female (66.1% [166 of
251]). Concomitant medications related to MS
(including treatments for AEs), most frequently
paracetamol, ibuprofen, and methylprednisolone,
were documented for 76.1% of patients (191 of
251). Most patients (87.3% [219 of 251]) opted to
administer serum-free SC IFN β-1a by using an auto-
injector, 7.6% (19 of 251) by manual injection, and
4.8% (12 of 251) by both methods. Data were missing
for 1 patient (0.4%).
Primary End Point: Proportion of Patients
With ISRs
Overall, 27.5% of patients (69 of 251) experienced




Patients who completed visit 2 (month 6)
(n = 217)
Patients who completed visit 3 (month 12)
(n = 196)
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1949







Mean (SD), y 35.8 (10.3)
Median (minimum, maximum), y 35.0 (17, 60)










Duration since MS diagnosis
No. 249
Mean (SD), mo 18 (40.8)
EDSS score
No. 236
Mean (SD) 1.64 (1.12)
Relapse episodes in the last 12
months
No. 246
Mean (SD) 1.6 (0.8)
Time since last relapse episode
No. 230
Mean (SD), mo 3.8 (2.4)
Q ¼ quartile; EDSS ¼ Expanded Disability Status Scale.
*Percentages are based on the total number of patients.
Clinical Therapeutics(n ¼ 30), reaction (n ¼ 17), pain (n ¼ 16), swelling
(n ¼ 3), hematoma (n ¼ 2), hemorrhage (n ¼ 1),
induration (n ¼ 1), pruritus (n ¼ 1), rash (n ¼ 1), and
abscess (n ¼ 1). Five patients discontinued treatment
because of ISRs that involved, pain, swelling, eryth-
ema, and induration; an additional patient discontin-
ued treatment due to injection site hematoma and
inﬂuenza-like illness. One patient interrupted treat-
ment because of mild pain and erythema at the
injection site. Most ISRs were mild (14.7% [37 of
251]) or moderate (11.2% [28 of 251]) in intensity; 4
patients experienced severe ISRs (1.6%). No serious
ISRs were reported. All ISRs were assessed as possibly
or probably related to administration of SC IFN β-1a.
Unexpectedly, female patients had higher odds of
experiencing ISRs compared with male patients (odds
ratio [OR], 2.15 [95% CI, 1.1–4.2]). Age, treatment
adherence at study end, mean dose per week, and




A total of 147 patients (58.6%) experienced a total
of 389 related AEs (assessed by the investigator to
have a possible, probable, or unlikely relationship
with SC IFN β-1a) (Table III). Seventeen patients
(6.8% [17 of 251]) cited AEs as the reason for
discontinuation of treatment; in 16 (6.4%) of these
patients, the AEs had an assumed causal relationship
with IFN β-1a.
Nonserious, related AEs reported in 41% of the
study population are shown in Table IV. The most
frequently reported related AEs were inﬂuenza-like
illness (30.3% [76 of 251]) and injection site erythema
(12.0% [30 of 251]), headache (9.2% [23 of 251]),
ISR (6.8% [17 of 251]), injection site pain (6.4% [16
of 251]), and fatigue (5.6% [14 of 251]). Seven
patients (2.8%) experienced 11 serious AEs (SAEs),
which led to discontinuation of treatment in 2 patients.
Only the SAE of psychotic disorder was dee-
med possibly related to treatment. No deaths occurred
during the study, and all patients recovered from SAEs
without sequelae. The investigators rated the overall
safety of SC serum-free IFN β-1a as excellent in 62.1%
(139 of 224), very good in 25.9% (58 of 224), and
good in 5.8% (13 of 224) of patients at the month 12/
ED visit. Tolerability was rated as excellent in 40.2%
(90 of 224), very good in 35.3% (79 of 224), and good1950in 11.6% (26 of 224) of patients. Overall, the safety
and tolerability of IFN β-1a were rated as excellent,
very good, or good in 485% of patients.
Adherence
Adherence data are summarized in Table V. The
proportion of patients with missed injections since the
previous visit was similar at the month 6 (20.3% [44
of 217]) and month 12/ED (21.0% [47 of 224]) visits.
The most common reason for missed injections wasVolume 36 Number 12





Patients with ISR, no. (%)† 69 (27.5)
95% CI 22.1–33.5




*All ISRs were assessed as treatment related (causal
relationship with subcutaneous interferon β-1a was
assessed by the investigator as possible, probable, or
unlikely).
†Percentages are based on the total number of patients
(safety population).
Table III. Summary of related adverse events
(AEs). Unless otherwise noted, data




No. of AEs 389
Patients with AEs* 147 (58.6)





Patients with nonserious AEs* 147 (58.6)
Patients with serious AEs* 5 (2.0)
No. of deaths 0
Patients who discontinued
treatment due to AE*
16 (6.4)
Related adverse events were assessed by the investigator
to have a possible, probable, or unlikely relationship
with subcutaneous interferon β-1a.
*Percentages are based on the total number of patients
(safety population).
†Each patient is counted only with the maximum
intensity.
Table IV. Nonserious, related adverse events
reported in 41% of patients. Data
are given as number (%).
MedDRA Preferred Term Total (N ¼ 251)
Inﬂuenza-like illness 76 (30.3)
Injection site erythema 30 (12.0)
Headache 23 (9.2)
Injection site reaction 17 (6.8)




Transaminase level increased 8 (3.2)
Pain in extremity 7 (2.8)
Liver function test abnormality 6 (2.4)






Injection site swelling 3 (1.2)
Nausea 3 (1.2)
Platelet count decreased 3 (1.2)
Sleep disorder 3 (1.2)
Skin reaction 3 (1.2)
MedDRA ¼ Medical Dictionary for Regulatory
Activities.
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December 2014“patient forgot to inject” (51.1% [24 of 224] at
month 12/ED), “patient did not want to have
injection” or “other” (both 19.1% [9 of 224]), “ﬂu-
like symptoms” (10.6% [5 of 224]), and “tired”
(6.4% [3 of 224]). Only 2 patients (4.3% [2 of 47])
cited “pain on injection site” as a reason for missed
injections, and 1 patient (2.1% [1 of 47]) cited “fear
of injection.” The investigators assessed adherence to
treatment at the month 6 visit as very good in 79.6%
(172 of 217) of patients, good in 13.0% (28 of 217),
and fair in 6.9% (15 of 217). At month 12/ED,
adherence was assessed as very good in 78.5% (175
of 224) of patients, good in 12.6% (28 of 224), and
fair in 7.2% (16 of 224). Investigators assessed
adherence as poor in 2 patients (0.9%).1951
Table V. Adherence to study medication.
Month 6 (n ¼ 217) Month 12/ED (n ¼ 224)
Patients with missed injections since last visit*
N 44 (20.3%) 47 (21.0%)
Percentage of missed injections†‡
N 209 219
Mean (SD) 0.9 (3.5) 0.7 (2.0)
Median (minimum, maximum) 0.0 (0, 30) 0.0 (0, 22)
Reasons for missed injections§ǁ
Forgot to inject 23 (52.3%) 24 (51.1%)
Tired 4 (9.1%) 3 (6.4%)
Fear of injection 1 (2.3%) 1 (2.1%)
Did not want to have injection 6 (13.6%) 9 (19.1%)
Pain on injection site 2 (4.5%) 2 (4.3%)
Flu-like symptoms 4 (9.1%) 5 (10.6%)
Other 14 (31.8%) 9 (19.1%)
Missing data 1 (2.3%) 0
Adherence to study medication*¶
Very good 172 (79.6%) 175 (78.5%)
Good 28 (13.0%) 28 (12.6%)
Fair 15 (6.9%) 16 (7.2%)
Poor 0 2 (0.9%)
Missing data 1 (0.5%) 2 (0.9%)
*Adherence: very good ¼ patient was always taking his or her medication as instructed by the physician; good ¼ patient was
taking his or her medication as instructed by the physician but forgot it once or twice since the previous visit; fair ¼
sometimes patient did not take the study medication properly or regularly; poor ¼ patient did not take the study
medication properly or regularly most of the time.
†Cumulative for month 12/early discontinuation visit.
‡One patient was excluded from the analysis because a value (247.8%, month 12) was considered implausible.
§Percentages are based on the number of patients with missed injections at the respective visit.
ǁMore than 1 reason could have been documented for a patient.
¶Percentages are based on the number of patients with the respective visit.
Clinical TherapeuticsDisease Activity
The results of the relapse assessments for the safety
population are summarized in Table VI. At month
12/ED, 71.7% (180 of 251) of patients were relapse-
free, and the mean ARR was 0.4 (1.0) (range, 0–9;
n ¼ 237).
Effect of Adherence on Disease Activity
A greater proportion of patients with very good or
good adherence (n ¼ 217) were relapse-free at month
12/ED (77.6% [170 of 219]) compared with those
with fair or poor adherence (50.0% [9 of 18];1952P ¼ 0.0107) (Figure 2A). However, because of the
low number of patients in the subgroup with fair or
poor adherence, this result should be interpreted with
caution. The ARR was signiﬁcantly lower in the
patient subgroup with very good or good adherence
versus fair or poor adherence (0.3 [1.0] vs 0.9 [1.2];
P ¼ 0.0055) (Figure 2B). There were no signiﬁcant
differences between the adherence subgroups with
regard to the mean time to onset of the ﬁrst episode
or mean duration of the episodes. In a multivariate
logistic regression analysis, the odds of a patient with
a fair or poor adherence experiencing a relapse epi-Volume 36 Number 12
Table VI. Relapse assessment.
Variable Total (N ¼ 251)
Relapse-free patients at month 6* 191 (76.1%)
Relapse-free patients at month 12/ED* 180 (71.7%)
Annualized relapse rate (normalized to 12 months)
No. of patients 237
Mean (SD) 0.4 (1.0)
Median (min, max) 0.0 (0, 9)
Time to onset of ﬁrst relapse, d
No. of patients 46
Mean (SD) 152.8 (113.3)
Median (min, max) 255 (4, 377)
Duration of relapse episode, d
No. of relapse episodes 53
Mean (SD) 35.2 (35.4)
Median (min, max) 22 (2, 154)
Total number of relapse episodes between baseline and month 6
No. of relapse episodes 35




Total no. of relapse episodes between month 6 and month 12/ED
No. of relapse episodes 31




Note: For the annualized relapse rate, the number of relapse episodes per patient was normalized to 12 months, regardless of
whether the patient discontinued the study earlier. Partial dates for “time to ﬁrst relapse” and “duration of relapse episodes”
were imputed.
ED ¼ early discontinuation; min ¼ minimum; max ¼ maximum.
*Percentages are based on the total number of patients.
†Percentages are based on the total number of relapse episodes in the respective time period.
R. Hupperts et al.sode during the study were 4.6 times higher than for
patients with very good or good adherence (OR, 4.58
[95% CI, 1.48–14.20]). A Cox proportional hazards
regression analysis identiﬁed signiﬁcant effect of
adherence on the time to onset of the ﬁrst relapse
episode, with hazard ratios (95% CI) of 3.20 (1.326–
7.739; P ¼ 0.0097) for good versus very good
adherence and 3.57 (1.313–9.720; P ¼ 0.0127) for
fair versus very good adherence.December 2014DISCUSSION
The aim of the present study was to assess the local
tolerability of SC serum-free IFN β-1a in patients with
RRMS in a minimally organized setting without the
frequent and regular medical surveillance commonly
performed in clinical trials. During the 12-month obser-
vation period, 27.5% of patients experienced nonserious
ISRs, which was comparable to, or lower than, that






































Figure 2. Effect of adherence on relapse activity.
(A) At the month 12/early discontinua-
tion visit, the proportion of relapse-free
patients in the subgroups with very
good/good adherence and fair/poor ad-
herence was 77.6% (170 of 219) and
50% (9 of 18), respectively (P ¼ 0.0107;
Fisher’s exact test). (B) The mean an-
nualized relapse rate (ARR) in the sub-
groups with very good/good adherence
and fair/poor adherence was 0.3 and
0.9, respectively (P ¼ 0.0055; Wilcoxon
rank sum test).
Clinical Therapeuticsin clinical studies (29.6% and 43.3% at 48 and 40
weeks, respectively, and 31% and 36% at 96 weeks and
2 years, respectively),21,22,26,27 demonstrating that the
good local tolerability of serum free SC IFN β-1a seen in
clinical studies is also observed in a real-life setting.
The observed discontinuation rate of 16.7% is at
the lower end of the expected range of 14% to 44%
when starting IFN β-1a therapy.28 Less than 2% of
patients in the study discontinued treatment due to1954ISRs, which accounted for 12% of AEs that led to early
discontinuation. These rates compare favorably with
ﬁndings of a hospital-based survey, which reported that
ISRs accounted for 16% of AEs leading to discontinua-
tion of IFN β administered by SC injection 3 times
weekly or weekly IM or SC injection.29 Data from
previous studies indicate that patients who discontinue
IFN β treatment because of AEs tend to do so soon after
therapy initiation (median, 13 months),29 and most
patients who discontinue or switch treatment from SC
IFN β-1a do so in the ﬁrst 12 months.2 Among patients
with MS treated with IFN β, the majority of treatment
interruptions occurred within the ﬁrst 6 months of
therapy,4 and ISRs with SC IFN β-1a were most
common during the ﬁrst month of treatment.30 Thus, the
1-year observation period in the present study is ad-
equate to assess the effect of local tolerability and general
safety of SC IFN β-1a on treatment discontinuation and
adherence.
The investigators rated the overall safety and toler-
ability of SC IFN β-1a during the study as excellent, very
good, or good in 487% of patients. AEs accounted for
45% of early discontinuations, which compares favor-
ably with a previous study, which reported that adverse
clinical reactions were responsible for 71.5% of discon-
tinuations of long-term treatment with SC IFN β-1a.31
The overall 63.7% incidence of AEs was lower than the
incidence of 76.6% to 95.0% observed in controlled MS
populations treated with the same serum-free SC IFN β-
1a formulation for a similar duration,26,27 demonstrating
that the good safety proﬁle and tolerability of SC IFN β-
1a reported in clinical studies were also observed in a
real-life setting. However, we could not rule out the
possibility of underreporting of AEs in an observational
study versus a randomized controlled trial setting; a
recent study reported that the mean incidence of ISRs
among patients receiving SC IFN β-1a in randomized
controlled trials was 70% (8%) versus 41% (30%) in
observational studies.32
More than 90% of patients in the study had very
good or good adherence. The most common reason
for nonadherence, cited by approximately one half of
the patients, was forgetting to administer the injection,
followed by not wanting to have an injection, which is
consistent with the ﬁndings of a multicenter, observa-
tional study.20 In the same study, 30% to 38% of
patients cited general injection-related problems, in-
cluding skin reaction and pain at the injection site, as
reasons for nonadherence to SC IFN β-1a. AlmostVolume 36 Number 12
R. Hupperts et al.90% of patients in the present study administered
IFN β-1a with an autoinjector. Findings from some
studies suggest that the use of injection devices may
help to overcome some injection-related barriers to
adherence. In a 12-week, observational study of 120
patients using an electronic autoinjection device to
self-administer serum-free SC IFN β-1a, the incidence
of ISRs was 10.6%, and490% of patients adhered to
treatment.33
More than 70% of the study population remained
relapse-free, and the mean ARR over the study period
was 0.4, which is comparable with outcomes in a
clinical study setting in which 66.8% of patients were
relapse-free after 48 weeks and the mean relapse rate
was 0.37.26 Adherent patients were more likely to be
relapse-free at the 6-month and 12-month/ED visits
and had a lower ARR compared with those with fair/
poor adherence. The difference in the number of
patients in the adherence subgroups is a source of
bias in the analysis; however, an increased risk of
relapse in patients who did not adhere to their MS
medication has also been reported in other studies.6–9
Our ﬁndings emphasize the need to adhere to SC IFN
β-1a treatment for the disease-modifying effects to be
realized and provide a strong rationale for attempting
to maximize treatment adherence.
Limitations of the study should be considered when
interpreting the ﬁndings. The electronic autoinjector
for SC IFN β-1a (RebiSmart, Merck Serono SA,
Geneva, Switzerland) was not available in all coun-
tries during the study period; therefore, adherence
data were not recorded automatically for all patients,
which could have resulted in patient-reporting errors.
We observed no signiﬁcant effect of adherence on the
mean time to onset of the ﬁrst relapse episode or mean
duration of relapse episodes. However, interpatient
variability for the mean time to onset of ﬁrst relapse
and the mean relapse duration was high (4–377 days
and 2–154 days, respectively,) and imputation of
partial dates in 11 patients resulted in inaccuracies
of up to 1 month, which could obscure differences in
these comparisons.
CONCLUSIONS
This study conﬁrmed that the good local and general
tolerability of SC serum-free IFN β-1a seen in clinical
studies were also observed in an international pop-
ulation in a real-life clinical setting. Adherence to
treatment was high, and adherent patients were moreDecember 2014likely to remain relapse-free, have a lower relapse rate,
and have a longer time to ﬁrst relapse than non-
adherent patients. These ﬁndings suggest that the
good local and general tolerability of SC serum-free
IFN β-1a may encourage good treatment adherence,
which is associated with better treatment outcomes.
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